A Promising Blood-Based Test for Early Detection of Colorectal Cancer

A study published in The New England Journal of Medicine on March 14, 2024, has revealed promising results for a non-invasive blood test designed to screen for colorectal cancer in adults. Colorectal cancer, which ranks third among most diagnosed cancers in the United States, could see a significant decline in mortality with early detection—a potential benefit that this new blood-based test offers to enhance current screening methods.

The research, led by Dr. Daniel C. Chung and a team of colleagues, focused on a cell-free DNA (cfDNA) blood-based test. The study sought to establish the test's reliability compared to the traditional screening colonoscopy.

Over 10,000 participants, eligible for colorectal cancer screening, were included in the analysis. The study revealed that the sensitivity of the cfDNA test for detecting colorectal cancer stood at 83.1% (with a 95% confidence interval [CI] of 72.2 to 90.3), while specificity for advanced neoplasia—encompassing colorectal cancer or advanced precancerous lesions—reached 89.6% (95% CI of 88.8 to 90.3). Impressively, the test detected all of the cases of stage II and III colorectal cancers in the study.

However, the sensitivity for advanced precancerous lesions was low at 13.2% (95% CI of 11.3 to 15.3), shedding light on the need for further refinement in detecting non-invasive, precancerous conditions with blood-based methods. The false positive rate of the test was determined to be 10.1%, pointing out that about 1 in 10 people with a negative colonoscopy had a positive test result.

This testing alternative presents an exciting development in colorectal cancer screening, particularly as it could potentially improve screening adherence among the eligible population—especially those reluctant or unable to undergo a colonoscopy.

The team emphasizes the need for ongoing studies to investigate patient adherence and to understand the blood test's effectiveness in different clinical settings. Additionally, implications for the expansion of screening to younger populations, as well as the test's possible integration into current screening guidelines, require further exploration to maximize its potential benefits.

This study highlights a noteworthy stride in the battle against colorectal cancer, with the cfDNA blood-based test offering a blend of ease, non-invasiveness, and considerable accuracy for early detection of this common and deadly cancer.

For a more detailed reading, please refer to the full study as published in The New England Journal of Medicine (NEJM), DOI: 10.1056/NEJMoa2304714.

Built with the help of Buoy Health.